In the first collaboration of its kind, the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority has brought on GlaxoSmithKline to help the federal agency develop new antibiotics to combat bioterrorism and growing resistance to the drugs.
According to an analysis by Bloomberg , Novartis is interested in finding a competitive Alzheimer's drug program. But it's hard to determine from the story if the pharma giant--always reluctant to detail partnering efforts or in-house strategies--has anything specific in mind.
Just a year or two ago, analysts and investors were in a frenzy over the frantic race to develop a new set of hepatitis C drugs that promised to change the standard of care. Now, as the leaders in that race approach the first round of likely marketing approvals, a new R&D competition has grabbed analysts' feverish attention as the next big thing in biopharma. And the leading players in this field may once again be betting on a mega-blockbuster payoff.
Researchers at Northwestern University have developed a technique to drill temporary holes in cell membranes to deliver drugs more easily into the cells.
Diagnosing the difference between pancreatic cancer and chronic pancreatitis is difficult because both conditions produce similar symptoms such as inflammation. But Mayo Clinic scientists say they've discovered a biomarker that will help make the job much easier down the line.
Johns Hopkins scientists believe two genes could serve as reliable epigenetic biomarkers for postpartum depression.
Alnylam Pharmaceuticals, a leader in the research and development of RNAi drug delivery, arrived at a successful proof-of-concept result for its gene-silencing treatment to temper a rare and deadly autosomal disease.
So, do drug companies really spend more money on marketing than on R&D? In the Pipeline takes a look at that contention, and the cold hard facts are these: Probably not. But it's hard to tell for sure.
Teva's new CEO, Jeremy Levin, has been touting the company's plan to come up with a pipeline of late-stage drugs that take well-known medicines and give them a makeover for new uses.
Any medication involves a balancing of risk and benefit. In areas where there is an unmet need, a little more risk might be acceptable. But the waters get muddy when two treatments, one offering better results but greater risks, are available for patients.